Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of tetrandrine in hepatic stellate cell migration inhibition drug preparation

A technology of hepatic stellate cells and tetrandrine, which is applied in the application field of medicine and can solve problems such as no relevant reports.

Inactive Publication Date: 2013-03-27
SHUGUANG HOSPITAL AFFILIATED WITH SHANGHAI UNIV OF T C M
View PDF0 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no relevant report on the role of tetrandrine in inhibiting the migration of hepatic stellate cells

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of tetrandrine in hepatic stellate cell migration inhibition drug preparation
  • Application of tetrandrine in hepatic stellate cell migration inhibition drug preparation
  • Application of tetrandrine in hepatic stellate cell migration inhibition drug preparation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0066] The tetrandrine of the present invention is made into tablets according to methods known to those skilled in the art. Tetrandrine tablets, each tablet contains 50mg of tetrandrine, 60mg of microcrystalline cellulose, 20mg of micronized silica gel, 10mg of lactose, and 0.7mg of magnesium stearate. Usage: 1 tablet each time, 2-3 times a day, 5-6 days a week, every 3-4 weeks as a course of treatment.

Embodiment 2

[0068] The tetrandrine of the present invention is made into capsules according to methods known to those skilled in the art. Tetrandrine capsules, each containing 50mg tetrandrine. Usage: 1 capsule each time, 2-3 times a day, 5-6 days a week, every 3-4 weeks as a course of treatment.

Embodiment 3

[0070] The tetrandrine of the present invention is prepared into granules according to methods known to those skilled in the art. Tetrandrine granules, each bag contains 50mg of tetrandrine, 60mg of microcrystalline cellulose, 20mg of micronized silica gel, 0.7mg of stearic acid, and 20mg of lactose. Usage: 1 bag each time, 2-3 times a day, 5-6 days a week, every 3-4 weeks as a course of treatment.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention discloses an application of tetrandrine in hepatic stellate cell migration inhibition drug preparation. According to the present invention, a PDGF-induced human hepatic stellate cell line (LX-2) migration screening platform is designed, and results show that PDGF-induced hepatic stellate cell (HSC) migration can be inhibited with 10<-4>-10<-7> mol / L tetrandrine.

Description

technical field [0001] The invention belongs to the field of traditional Chinese medicines, and in particular relates to the application of tetrandrine in the preparation of medicines for inhibiting the migration of hepatic stellate cells. Background technique [0002] Tetrandrine, also known as tetrandrine, is the main biologically active component of Tetradontidae plant, belonging to the bisbenzyl isoquinoline compound, is Ca 2+ Antagonist, which can both block membrane voltage-gated channel-mediated Ca 2+ Influx, can also block receptor-gated channels interfering with intracellular Ca 2+ distribution, thereby blocking relevant pathological processes; such as inhibiting the proliferation of fibroblasts, the synthesis and excretion of ECM (extracellular matrix, extracellular matrix), and the promotion of fibrosis by growth factors. Studies have found that it has a good therapeutic effect on the cardiovascular system, liver, pulmonary fibrosis, and inflammatory response. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4748A61P1/16
Inventor 徐列明张展
Owner SHUGUANG HOSPITAL AFFILIATED WITH SHANGHAI UNIV OF T C M
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com